189 related articles for article (PubMed ID: 30224328)
21. The role of high serum CXCL13 level in Waldenström macroglobulinemia.
Wu YY; Cai H; Zhao AL; Zhang L; Zhou DB; Cao XX; Li J
Leuk Res; 2019 Jun; 81():50-55. PubMed ID: 31015152
[TBL] [Abstract][Full Text] [Related]
22. The epidemiology of Waldenström macroglobulinemia.
McMaster ML
Semin Hematol; 2023 Mar; 60(2):65-72. PubMed ID: 37099032
[TBL] [Abstract][Full Text] [Related]
23. Waldenström's macroglobulinemia.
Dimopoulos MA; Galani E; Matsouka C
Hematol Oncol Clin North Am; 1999 Dec; 13(6):1351-66. PubMed ID: 10626154
[TBL] [Abstract][Full Text] [Related]
24.
Poulain S; Roumier C; Bertrand E; Renneville A; Caillault-Venet A; Doye E; Geffroy S; Sebda S; Nibourel O; Nudel M; Herbaux C; Renaud L; Tomowiak C; Guidez S; Tricot S; Roche-Lestienne C; Quesnel B; Preudhomme C; Leleu X
Clin Cancer Res; 2017 Oct; 23(20):6325-6335. PubMed ID: 28754818
[No Abstract] [Full Text] [Related]
25. Differential diagnosis of Waldenstrom's macroglobulinemia and other B-cell disorders.
Pangalis GA; Kyrtsonis MC; Kontopidou FN; Siakantaris MP; Dimopoulou MN; Vassilakopoulos TP; Tzenou T; Kokoris S; Dimitriadou E; Kalpadakis C; Tsalimalma K; Tsaftaridis P; Panayiotidis P; Angelopoulou MK
Clin Lymphoma; 2005 Mar; 5(4):235-40. PubMed ID: 15794855
[TBL] [Abstract][Full Text] [Related]
26. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack.
Crawley JT; Lane DA; Woodward M; Rumley A; Lowe GD
J Thromb Haemost; 2008 Apr; 6(4):583-8. PubMed ID: 18194418
[TBL] [Abstract][Full Text] [Related]
27. Angiogenesis in Waldenström's macroglobulinemia.
Terpos E; Tasidou A; Kastritis E; Eleftherakis-Papaiakovou E; Gavriatopoulou M; Migkou M; Dimopoulos MA
Clin Lymphoma Myeloma; 2009 Mar; 9(1):46-9. PubMed ID: 19362971
[TBL] [Abstract][Full Text] [Related]
28. Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenstrom macroglobulinaemia.
Pasricha SR; Juneja SK; Westerman DA; Came NA
J Clin Pathol; 2011 Jun; 64(6):520-3. PubMed ID: 21471142
[TBL] [Abstract][Full Text] [Related]
29. Smouldering Waldenstrom's macroglobulinemia: factors predicting evolution to symptomatic disease.
Cesana C; Miqueleiz S; Bernuzzi P; Tresoldi E; Rossi V; D'avanzo G; Filippini D; Morra E
Semin Oncol; 2003 Apr; 30(2):231-5. PubMed ID: 12720142
[TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders.
Morra E; Cesana C; Klersy C; Barbarano L; Varettoni M; Cavanna L; Canesi B; Tresoldi E; Miqueleiz S; Bernuzzi P; Nosari AM; Lazzarino M
Leukemia; 2004 Sep; 18(9):1512-7. PubMed ID: 15322559
[TBL] [Abstract][Full Text] [Related]
31. The malignant clone in Waldenstrom's macroglobulinemia.
Kriangkum J; Taylor BJ; Mant MJ; Treon SP; Belch AR; Pilarski LM
Semin Oncol; 2003 Apr; 30(2):132-5. PubMed ID: 12720122
[TBL] [Abstract][Full Text] [Related]
32. [Lymphoplasmacytic lymphoma: a clinicopathological and prognostic analysis of 27 cases].
Chen Y; Zhang F; Wu HM; Luo XL; Zhang KP; Liu YH
Zhonghua Bing Li Xue Za Zhi; 2021 Dec; 50(12):1346-1352. PubMed ID: 34865422
[No Abstract] [Full Text] [Related]
33. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia.
Ciccarelli BT; Yang G; Hatjiharissi E; Ioakimidis L; Patterson CJ; Manning RJ; Xu L; Liu X; Tseng H; Gong P; Sun J; Zhou Y; Treon SP
Clin Lymphoma Myeloma; 2009 Mar; 9(1):56-8. PubMed ID: 19362974
[TBL] [Abstract][Full Text] [Related]
34. Asymptomatic Waldenstrom's macroglobulinemia.
Alexanian R; Weber D; Delasalle K; Cabanillas F; Dimopoulos M
Semin Oncol; 2003 Apr; 30(2):206-10. PubMed ID: 12720137
[TBL] [Abstract][Full Text] [Related]
35. The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemia.
Dimopoulos M; Gika D; Zervas K; Kyrtsonis M; Symeonidis A; Anagnostopoulos A; Bourantas K; Matsouka C; Pangalis G
Leuk Lymphoma; 2004 Sep; 45(9):1809-13. PubMed ID: 15223640
[TBL] [Abstract][Full Text] [Related]
36. Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?
Gobbi PG; Baldini L; Broglia C; Goldaniga M; Comelli M; Morel P; Morra E; Cortelazzo S; Bettini R; Merlini G
Clin Cancer Res; 2005 Mar; 11(5):1786-90. PubMed ID: 15756000
[TBL] [Abstract][Full Text] [Related]
37. Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling.
Argyropoulos KV; Vogel R; Ziegler C; Altan-Bonnet G; Velardi E; Calafiore M; Dogan A; Arcila M; Patel M; Knapp K; Mallek C; Hunter ZR; Treon SP; van den Brink MR; Palomba ML
Leukemia; 2016 May; 30(5):1116-25. PubMed ID: 26867669
[TBL] [Abstract][Full Text] [Related]
38. Changes in von Willebrand factor and ADAMTS-13 in patients following arthroplasty.
Liu L; Ling J; Ma Z; Yuan Q; Pan J; Yang H
Mol Med Rep; 2015 Apr; 11(4):3015-20. PubMed ID: 25482054
[TBL] [Abstract][Full Text] [Related]
39. Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia.
Bustoros M; Sklavenitis-Pistofidis R; Kapoor P; Liu CJ; Kastritis E; Zanwar S; Fell G; Abeykoon JP; Hornburg K; Neuse CJ; Marinac CR; Liu D; Soiffer J; Gavriatopoulou M; Boehner C; Cappuccio JM; Dumke H; Reyes K; Soiffer RJ; Kyle RA; Treon SP; Castillo JJ; Dimopoulos MA; Ansell SM; Trippa L; Ghobrial IM
J Clin Oncol; 2019 Jun; 37(16):1403-1411. PubMed ID: 30990729
[TBL] [Abstract][Full Text] [Related]
40. Establishment of an animal model for Waldenström's macroglobulinemia.
Tsingotjidou AS; Emmanouilides CE; Siotou E; Poutahidis T; Xagorari A; Loukopoulos P; Sotiropoulos D; Bekiari C; Doulberis M; Givissis P; Fassas A; Anagnostopoulos A
Exp Hematol; 2009 Apr; 37(4):469-76. PubMed ID: 19302921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]